ArticleJournal of Cancer2018

Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma.

Xingming Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.